Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July

Mina Sooch CEO to Present at Ophthalmic Innovation Panel at the 11 th Annual AECOS Summer Symposium and OIS Retina Innovation Summit ASRS Late-Breaking Paper Highlighting Data from Two Phase 3 Registration Trials in Reversal of Mydriasis for Nyxol Second ASRS Presentation Features New Interim Masked Safety Data from APX3330 Phase 2b Trial in Diabetic Retinopathy Ocuphire to Present at OCTANE and at the National Medical Association (NMA)'s Annual Convention and Scientific Assembly FARMINGTON HILLS, Mich., July 07, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP ), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced six presentations in July at American-European Congress of Ophthalmic Surgery (AECOS), American Society of Retina Specialists (ASRS), Ophthalmology Innovation Summit (OIS), Octane and National Medical Association (NMA). At ASRS 2022 in New York, key thought leader David Boyer, MD will present for the first time to the retina medical community a late-breaking paper highlighting data from two Phase 3 registration trials in the reversal of mydriasis/dilation for Nyxol. In addition to the late-breaking presentation, Michael Allingham, MD, Ph.D. will present new interim masked safety data for APX3330 from ZETA-1 Phase 2b trial in diabetic retinopathy. 11th Annual AECOS Summer Symposium Panel: Ophthalmic Innovation Forum Date: Saturday, July 9, 2022, 8:10 AM – 10:00 AM MDT Presenter: Mina Sooch, MBA, CEO Location: St Regis Hotel, Deer Valley, Utah Link: 11 th Annual AECOS Summer Symposium Ophthalmology Innovation Summit OIS Retina 2022 Session: Innovation Showcase Date: Wednesday, July 13, 2022, 8:50 AM – 10:15 AM EDT Full story available on Benzinga.com